Abraxana has emerged as a more effective breast cancer treatment compared to Taxotere, researchers have discovered.
Findings by scientists at Northwestern University in the US showed that the less toxic, solvent-free chemotherapy drug is more capable of preventing the progression of metastatic breast cancer than the more commonly used solvent-based treatment.
It was also revealed that Abraxane has fewer side effects than its counterpart.
Study leader William Gradishar said the findings were "win-win".
"The weekly schedule of Abraxane has more anti-tumour effects and is better tolerated than Taxotere," he explained.
"There is also evidence that Abraxane is able to deliver the chemotherapy drug more effectively to the tumour."
Without containing chemical solvents, Abraxane uses albumin, a human protein, to deliver chemotherapy treatment.
Metastatic breast cancer involves the spread of a malignant tumour from the breast to other parts of the body.
A total of 45,000 women were diagnosed with breast cancer in the UK in 2006, making it the most common form of the disease in the country.